[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Ningbo No. 1 Hospital\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":219},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,8,0,[8,50,77,105,128,153,177,196],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":31,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":39,"lastUpdatePostDateStruct":40,"startDateStruct":43,"completionDateStruct":45,"leadSponsor":47,"locationsCount":4},"100606915","clinical-trial-of-visor-vs-furs-for-upper-urinary-tract-stone-100606915",false,"NCT07181759","Clinical Trial of VISOR vs fURS for Upper Urinary Tract Stone","Prospective Randomized Controlled Clinical Trial on the Treatment of Upper Urinary Tract Stones With VISOR and fURS","VISOR","Inclusion Criteria:\n\n* Patients with upper urinary tract stones and a cumulative stone diameter ≤3 cm;\n* Patients scheduled to undergo \"flexible ureteroscopic holmium laser lithotripsy\";\n* Age ≥18 years;\n* Patients without psychiatric disorders or language dysfunction, capable of understanding the study and providing informed consent.\n\nExclusion Criteria:\n\n* Patients requiring bilateral lithotripsy in a single-stage ureteroscopic procedure;\n* Ipsilateral hydronephrosis with \\>4 cm renal pelvic separation;\n* Patients with a history of open or laparoscopic renal and\u002For ureteral surgery;\n* Fever (body temperature ≥38°C) due to urinary tract infection or other causes within one week prior to surgery;\n* Pregnant women;\n* Patients with severe systemic diseases, cardiac diseases, pulmonary insufficiency, or vital organ failure unable to tolerate anesthesia or surgery (ASA score ≥3);\n* Patients with anatomical abnormalities such as polycystic kidney, horseshoe kidney, or ectopic kidney;\n* Patients with coagulation disorders (e.g., INR \\>2.0 or platelet count \\\u003C80×10⁹\u002FL);\n* Patients currently participating in other device or drug clinical trials;\n* Patients deemed ineligible for the trial by the investigator.","ALL","18 Years",{"count":20,"type":21},100,"ESTIMATED","INTERVENTIONAL",[24],"NA","This prospective randomized controlled clinical study aims to evaluate the safety and efficacy of a novel Vortex Intelligence Stone Optimized Removal (VISOR,The experimental group) system compared to a single-use ureterorenoscope (the control) for treating upper urinary tract stones.\n\nA total of 100 patients with upper urinary tract stones (cumulative stone diameter ≤3 cm) will be enrolled and randomly assigned in a 1:1 ratio to either the experimental group (n=50) or the control group (n=50). The experimental group will undergo surgery using the innovative system, which integrates irrigation-suction, pressure monitoring-regulation, and lithotripsy-evacuation functions. The control group will be treated with a conventional single-use ureterorenoscope.\n\nThe primary outcome measure is the immediate stone-free rate (SFR), defined as the proportion of patients with residual fragments \\\u003C4 mm on renal non-contrast computed tomography (NCCT) performed within 24 hours postoperatively. Key secondary endpoints include the SFR at 3 months, operative and lithotripsy times, total laser energy used, intraoperative ureteral injury (Traxer grading), postoperative pain scores, incidence of fever (\\>38.0°C), and overall complication rates (Clavien-Dindo classification).\n\nPatient follow-up assessments will be conducted at 24 hours, 21±7 days, and 90±14 days post-surgery to monitor stone clearance, complications, and recovery. This study seeks to determine if the novel system offers superior stone clearance while maintaining a safe renal pelvic pressure profile, potentially improving outcomes for patients with larger renal stones treated ureteroscopically.",[27,28,29,30],"Urolithiasis, Calcium Oxalate","Ureteroscopy","Therapeutic Irrigation","Intraoperative Complications",[32,33,34,35,36,15,37],"Ureterorenoscopy","Upper urinary tract calculi","Intrarenal pressure","Stone-free rate (SFR)","Lithotripsy","Vortex intelligence Stone Optimized Removal(VISOR）","NOT_YET_RECRUITING","2025-09-12",{"date":41,"type":42},"2025-09-18","ACTUAL",{"date":44,"type":21},"2025-09-20",{"date":46,"type":21},"2026-12-31",{"name":48,"class":49},"Ningbo No. 1 Hospital","OTHER",{"id":51,"slug":52,"hasResults":11,"nctId":53,"briefTitle":54,"officialTitle":55,"acronym":4,"eligibilityCriteria":56,"healthyVolunteers":11,"sex":17,"minAge":57,"maxAge":58,"enrollmentInfo":59,"targetDuration":4,"studyType":61,"phases":4,"briefSummary":62,"conditions":63,"keywords":4,"overallStatus":67,"whyStopped":4,"lastUpdateSubmitDate":68,"lastUpdatePostDateStruct":69,"startDateStruct":71,"completionDateStruct":73,"leadSponsor":75,"locationsCount":76},"100591752","accelerated-biological-aging-is-associated-with-increased-risk-of-t2dm-in-the-masld-population-100591752","NCT06984510","Accelerated Biological Aging is Associated With Increased Risk of T2DM in the MASLD Population","Accelerated Biological Aging is Associated With Increased Risk of T2DM in the MASLD Population: a Cohort Study","Inclusion Criteria:\n\n1. Abdominal ultrasound data available in annual health check-up records\n2. At least one of the following five metabolic indicators recorded annually:\n\n(1) Body mass index (BMI) or waist circumference (2) Blood pressure (3) Serum triglycerides (4) High-density lipoprotein cholesterol (HDL-C) (5) Fasting plasma glucose or glycated hemoglobin (HbA1c)\n\nExclusion Criteria:\n\n1. Age \\\u003C20 or \\>90 years\n2. Other causes of hepatic steatosis (e.g., alcoholic liver disease or hepatitis B infection)\n3. Type 2 diabetes mellitus at baseline\n4. Missing baseline data for any of the following variables: systolic blood pressure, albumin, alkaline phosphatase, blood urea nitrogen, creatinine, glycated hemoglobin (HbA1c), total cholesterol, lymphocyte percentage, white blood cell count, mean corpuscular volume, uric acid, fasting plasma glucose, and red cell distribution width (RDW)","20 Years","90 Years",{"count":60,"type":21},2720,"OBSERVATIONAL","The association between biological aging and type 2 diabetes mellitus (T2DM) incidence in individuals with and without metabolic dysfunction-associated steatotic liver disease (MASLD) remains unclear.We assessed biological age by calculating phenotypic age (PhenoAge), Klemera-Doubal method (KDMAge), and homeostatic dysregulation (HDAge). To examine the association of biological ageing with the risk of T2DM, cox regression models were conducted. Furthermore, we applied survival analysis, restricted cubic spline models and population attributable fraction (PAF) to further evaluate the association between biological ageing and T2DM incidence.",[64,65,66],"Type 2 Diabetes Mellitus (T2DM)","Metabolic Dysfunction-Associated Steatotic Liver Disease","Biological Age","RECRUITING","2025-05-30",{"date":70,"type":42},"2025-06-04",{"date":72,"type":42},"2025-04-01",{"date":74,"type":21},"2025-12-31",{"name":48,"class":49},1,{"id":78,"slug":79,"hasResults":11,"nctId":80,"briefTitle":81,"officialTitle":82,"acronym":4,"eligibilityCriteria":83,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":84,"enrollmentInfo":85,"targetDuration":4,"studyType":22,"phases":87,"briefSummary":88,"conditions":89,"keywords":93,"overallStatus":67,"whyStopped":4,"lastUpdateSubmitDate":97,"lastUpdatePostDateStruct":98,"startDateStruct":100,"completionDateStruct":102,"leadSponsor":104,"locationsCount":76},"100592002","comparing-different-diameter-furss-with-similar-resds-for-the-treatment-of-upper-urinary-tract-stones-100592002","NCT06987760","Comparing Different Diameter fURSs With Similar RESDs for the Treatment of Upper Urinary Tract Stones","Comparing Different Diameter fURSs With Similar RESDs for the Treatment of Upper Urinary Tract Stones - A Randomized Controlled Multi-center Clinical Trials","Inclusion Criteria:\n\n\\- 1.Patients with kidney stones or upper ureteral stones with a cumulative diameter of less than 3 cm are selected for ureteral soft lens holmium laser lithotripsy.\n\n2.Age 18 to 80 years old, gender unlimited. 3.The subjects have no mental illness or language dysfunction, can understand the situation of the study and can sign informed consent.\n\nExclusion Criteria:\n\n* 1.Patients with a history of ureteral stenosis or who have undergone open or laparoscopic ureteral or renal lithotomy.\n\n  2.Patients with fever one week before surgery 3.Pregnant women and menstruating patients. 4.Patients with combined systemic disease or inability to tolerate anesthesia. 5.Patients undergoing simultaneous surgery for bilateral upper urinary tract stones.\n\n  6.Patients with ureteral stent indwelling before surgery. 7.In patients with severe hydronephrosis, the separation of the renal collecting system is greater than 4 cm.\n\n  8.Patients with renal anatomic malformations such as polycystic kidney, horseshoe kidney, and ectopic kidney.","80 Years",{"count":86,"type":21},206,[24],"Comparing the Efficiency, Effectiveness, and Safety of fURS lithotripsy with Similar RESDs in the Treatment of Upper Urinary Tract Stones.",[90,91,92],"Ureter Injury","Urolithiasis; Lower Urinary Tract","Efficacy, Self",[94,95,96],"Urolithiasis","Ratio of Endoscope-Sheath Diameter","Flexible ureteroscope","2025-05-22",{"date":99,"type":42},"2025-05-23",{"date":101,"type":42},"2025-03-19",{"date":103,"type":21},"2026-12-30",{"name":48,"class":49},{"id":106,"slug":107,"hasResults":11,"nctId":108,"briefTitle":109,"officialTitle":110,"acronym":4,"eligibilityCriteria":111,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":112,"enrollmentInfo":113,"targetDuration":4,"studyType":22,"phases":115,"briefSummary":116,"conditions":117,"keywords":4,"overallStatus":67,"whyStopped":4,"lastUpdateSubmitDate":120,"lastUpdatePostDateStruct":121,"startDateStruct":123,"completionDateStruct":125,"leadSponsor":127,"locationsCount":76},"100523588","underwater-endoscopic-mucosal-resection-versus-metal-clips-with-hot-snare-polypectomy-for-resection-of-big-pedunculated-colorectal-polyps-100523588","NCT06097637","Underwater Endoscopic Mucosal Resection Versus Metal Clips With Hot Snare Polypectomy for Resection of Big Pedunculated Colorectal Polyps","Underwater Endoscopic Mucosal Resection Versus Metal Clips With Hot Snare Polypectomy for Resection of Big Pedunculated Colorectal Polyps: A Randomized Controlled Trial","Inclusion Criteria:\n\n1. Patients undergoing endoscopic resection of small and medium pedicled polyps in the First Affiliated Hospital of Ningbo University from October 2023 to August 2026;\n2. Age 18-75 years old;\n3. Patients who voluntarily agreed to participate in this study and signed informed consent.\n\nExclusion Criteria:\n\n1. Persons under 18 years of age\n2. Persons unwilling or unable to provide informed consent\n3. Treatment or radiotherapy for malignant diseases, severe chronic heart or lung diseases, coronary or cerebrovascular events requiring hospitalization within the last 3 months\n4. Malignant polyps have infiltrated the pedicle\n5. Abdominal symptoms such as severe abdominal pain, abdominal distension, and nausea\n6. Patients with inadequate intestinal preparation\n7. Patients with lifelong anticoagulant therapy or severe bleeding diseases, patients who have recently taken anticoagulant drugs or antiplatelet drugs (within 1 week)\n8. Pregnant or lactating","75 Years",{"count":114,"type":21},156,[24],"Endoscopic resection of pedunculated polyps mainly focuses on how to prevent bleeding, and also needs to pay attention to the convenience of resection and the integrity of resection, which means that different endoscopic resection strategies should be adopted for pedunculated polyps with different pedicle sizes. The head larger than 20mm or pedicle larger than 5mm are defined as large pedunculated polyps, which are at greater risk of bleeding. Current guidelines recommend hot removal by snare following preoperative saline injection, ligation of the pedicle with a nylon ring or metal clip, depending on the size of the polyp head and pedicle. However, the use of snares and metal clamps does not appear to reduce delayed postoperative bleeding, and the technical requirements of nylon ligation are relatively high. Recent studies have found that Underwater endoscopic mucosal resection (UEMR) is also safe and effective for the treatment of large and medium colorectal sessile polyps. Therefore, it is still necessary to further explore new safe and effective endoscopic resection strategies and techniques.",[118,119],"Pedunculated Colorectal Polyps","Haemorrhage","2024-12-17",{"date":122,"type":42},"2024-12-18",{"date":124,"type":42},"2023-10-19",{"date":126,"type":21},"2026-08-31",{"name":48,"class":49},{"id":129,"slug":130,"hasResults":11,"nctId":131,"briefTitle":132,"officialTitle":133,"acronym":4,"eligibilityCriteria":134,"healthyVolunteers":11,"sex":17,"minAge":135,"maxAge":84,"enrollmentInfo":136,"targetDuration":4,"studyType":22,"phases":138,"briefSummary":139,"conditions":140,"keywords":142,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":146,"lastUpdatePostDateStruct":147,"startDateStruct":148,"completionDateStruct":150,"leadSponsor":152,"locationsCount":4},"100567190","vitamin-cs-antioxidant-effects-and-copd-prognosis-100567190","NCT06664957","Vitamin C's Antioxidant Effects and COPD Prognosis","The Role of the Antioxidant Effects of Vitamin C in Improving the Prognosis of Patients With Chronic Obstructive Pulmonary Disease: A Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study.","Inclusion Criteria:\n\n1. Age 40-80 years (including 40 and 80).\n2. Patients with COPD classified as GOLD stages 2-4:\n\n   Post-bronchodilator FEV1\u002FFVC \\\u003C 70% and FEV1 \\\u003C 80% of predicted value.\n3. No respiratory infection or acute exacerbation of COPD within 4 weeks prior to enrollment. Acute exacerbation is defined as an acute worsening of respiratory symptoms requiring additional treatment.\n4. The patient voluntarily consents to participate in the study, is capable of verbal or written communication, and can understand and sign the informed consent form. The patient must also be able to complete the necessary assessments required for the study.\n\nExclusion Criteria:\n\n1. Presence of other respiratory diseases such as alpha-1 antitrypsin deficiency, primary ciliary dyskinesia, active pulmonary infection (e.g., tuberculosis), lung cancer, pulmonary fibrosis, cystic fibrosis, obesity hypoventilation syndrome, sarcoidosis, pulmonary hypertension, or clinically significant interstitial lung disease (patients with COPD as the primary disease and comorbid bronchiectasis may be included).\n2. History of asthma or asthma-COPD overlap syndrome: Patients currently diagnosed with asthma, according to GINA or other recognized guidelines, will be excluded. Patients with a childhood history of asthma (defined as diagnosis before age 18 and fully resolved) may be included.\n3. History of lung resection or expected need for lung volume reduction surgery during the study.\n4. Clinically significant abnormalities on chest CT that are not attributable to COPD.\n5. Presence of clinically significant cardiovascular, neurological, psychiatric, renal, hepatic, immunological, gastrointestinal, genitourinary, musculoskeletal, dermatological, sensory, endocrine diseases, or hematological abnormalities, as judged by the investigator, that may affect patient safety or confound the effectiveness or safety analysis during the study.\n6. Unstable cardiac disease: Patients will be excluded if they have any of the following conditions: a. Myocardial infarction, unstable angina\u002Facute coronary syndrome, coronary artery bypass graft (CABG) surgery, or percutaneous coronary intervention (PCI) within the past 6 months. b. Structural heart disease such as hypertrophic cardiomyopathy or significant valvular disease. c. Unstable or life-threatening arrhythmias requiring intervention within the past 3 months. d. NYHA class II-IV heart failure.\n7. Active malignancy: Patients with active cancer will be excluded.\n8. Recent Vitamin C use: Patients who have used Vitamin C supplements within the last 4 weeks will be excluded.\n9. Diabetes: Patients with poorly controlled diabetes or fasting blood glucose \\> 10 mmol\u002FL will be excluded.\n10. History of kidney stones or diagnosis of kidney stones within the past year, as high doses of Vitamin C may increase the risk of stone formation.","40 Years",{"count":137,"type":21},650,[24],"This multicenter, randomized, double-blind, placebo-controlled clinical trial aims to evaluate the efficacy of Vitamin C supplementation in improving the prognosis of patients with Chronic Obstructive Pulmonary Disease (COPD) through its antioxidant effects.\n\nThe primary objectives of the study are to determine:\n\n1. Whether Vitamin C reduces the frequency of acute COPD exacerbations.\n2. Whether Vitamin C improves pulmonary function and health-related quality of life in patients with COPD.\n\nThe study will compare Vitamin C to a placebo to assess its impact on oxidative stress and its potential to enhance clinical outcomes in COPD management.\n\nParticipants will:\n\n1. Receive either daily oral Vitamin C supplementation or a placebo for a period of 6 months. Undergo monthly clinical evaluations, including spirometry and symptom assessments.\n2. Report any adverse events or health changes during the trial.",[141],"COPD (Chronic Obstructive Pulmonary Disease)",[143,144,145],"Vitamin C","Antioxidant Effects","Prognosis","2024-12-15",{"date":120,"type":42},{"date":149,"type":21},"2024-12-20",{"date":151,"type":21},"2026-02-28",{"name":48,"class":49},{"id":154,"slug":155,"hasResults":11,"nctId":156,"briefTitle":157,"officialTitle":158,"acronym":4,"eligibilityCriteria":159,"healthyVolunteers":11,"sex":17,"minAge":135,"maxAge":84,"enrollmentInfo":160,"targetDuration":4,"studyType":22,"phases":162,"briefSummary":163,"conditions":164,"keywords":166,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":170,"lastUpdatePostDateStruct":171,"startDateStruct":173,"completionDateStruct":175,"leadSponsor":176,"locationsCount":4},"100563154","interleukin-6-guided-antibiotic-prescriptions-in-aecopd-inpatients-100563154","NCT06612476","Interleukin 6-guided Antibiotic Prescriptions in AECOPD Inpatients","Interleukin 6-guided Antibiotic Prescriptions in AECOPD Inpatients: a Multicenter Randomized Controlled Trial","Inclusion Criteria:\n\n1. AECOPD patients admitted to hospitals\n2. The exacerbation has lasted for at least 24 hours but equal to or less than 21 days\n3. ≥40 years of age but no more than 80 years old\n4. With at least 10 pack-year history of smoking\n5. Able to provide written informed consent and ensure the completion of the trial\n\nExclusion Criteria:\n\n1. Axillary temperature≥38°C\n2. Acute pneumonia identified by X-Ray or CT of the chest\n3. Severe respiratory failure requiring admittance to ICU\n4. Comorbidities require antibiotic therapy (i.e. infection at another site, systematic infection, active chronic inflammatory condition, specific viral infection)\n5. Immunosuppression status (i.e., patients with HIV infection, with malignant tumor of blood system, receiving chemotherapy)\n6. Concurrent diseases requiring corticosteroids (equivalent to 60mg prednisone\u002Fday or more than 30 days)\n7. Antibiotic use in the previous four weeks\n8. Current tracheotomy status\n9. Bronchiectasis of origin other than COPD\n10. Invasive mechanical ventilation\n11. Patients diagnosed malignant tumors\n12. Pregnant or lactating women, or women of childbearing age not using an acceptable method of contraception.\n13. Newly diagnosed pulmonary embolism\n14. Participation in another clinical trial",{"count":161,"type":21},440,[24],"In this multicenter, prospective, randomized controlled study, we aimed to figure out, compared with the global chronic obstructive pulmonary disease initiative (GOLD) guideline -guided antibiotic therapy, whether Interleukin 6 (IL6)-guided antibiotic therapy for acute exacerbation of chronic obstructive pulmonary disease (AECOPD) can lead to a reduction in the use of antibiotics without increasing the rate of treatment failure.",[165],"Chronic Obstructive Pulmonary Disease, COPD",[167,168,169],"Aecopd","Interleukin 6","antibiotic therapy","2024-09-21",{"date":172,"type":42},"2024-09-25",{"date":174,"type":21},"2024-09-20",{"date":126,"type":21},{"name":48,"class":49},{"id":178,"slug":179,"hasResults":11,"nctId":180,"briefTitle":181,"officialTitle":181,"acronym":4,"eligibilityCriteria":182,"healthyVolunteers":11,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":183,"targetDuration":4,"studyType":61,"phases":4,"briefSummary":185,"conditions":186,"keywords":4,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":188,"lastUpdatePostDateStruct":189,"startDateStruct":191,"completionDateStruct":193,"leadSponsor":195,"locationsCount":76},"100558909","the-application-of-the-pdca-management-model-in-improving-the-diagnostic-accuracy-of-aig-100558909","NCT06557252","The Application of the PDCA Management Model in Improving the Diagnostic Accuracy of AIG","Inclusion Criteria:\n\nEndoscopy center gastroenterologists in our hospital in 2024\n\nExclusion Criteria:\n\nDoctors who withdrew from the PDCA management midway and stopped undergoing gastroscopy.",{"count":184,"type":21},16,"Autoimmune gastritis is currently relatively rare in China due to its insidious onset, diverse clinical manifestations involving multiple systems such as digestive, hematological, and nervous systems, and its association with other autoimmune diseases. It can also be complicated by hyperplastic gastric polyps, gastric neuroendocrine tumors, gastric adenocarcinoma, and other diseases, making it prone to clinical misdiagnosis. As a form of gastritis in the post-Helicobacter pylori era, its detection rate has been gradually increasing with the continuous improvement of endoscopic technology in China. Applying the PDCA cycle management in disease diagnosis can significantly improve the detection rate of the disease, benefiting patients. Through the PDCA management model, this study further enhanced gastroenterologists' understanding of this disease from various aspects, aiming to improve the clinical diagnosis of autoimmune gastritis.",[187],"Autoimmune Gastritis","2024-08-13",{"date":190,"type":42},"2024-08-16",{"date":192,"type":21},"2024-08-15",{"date":194,"type":21},"2024-12-31",{"name":48,"class":49},{"id":197,"slug":198,"hasResults":11,"nctId":199,"briefTitle":200,"officialTitle":201,"acronym":4,"eligibilityCriteria":202,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":112,"enrollmentInfo":203,"targetDuration":4,"studyType":22,"phases":205,"briefSummary":207,"conditions":208,"keywords":4,"overallStatus":67,"whyStopped":4,"lastUpdateSubmitDate":210,"lastUpdatePostDateStruct":211,"startDateStruct":213,"completionDateStruct":215,"leadSponsor":217,"locationsCount":218},"100489938","phase-1-cd19-car-t-expressing-il-7-and-ccl19-combined-with-anti-pd1-in-rr-dlbcl-100489938","NCT05659628","CD19 CAR-T Expressing IL-7 and CCL19 Combined With Anti-PD1 in RR-DLBCL","Phase Ib Clinical Study of CD19 CAR-T Expressing IL-7 and CCL19 Combined With Tislelizumab in the Treatment of Relapsed\u002FRefractory Diffuse Large B-cell Lymphoma","Inclusion Criteria:\n\n1. Age ≥ 18, upper limit 75, male or female;\n2. ECOG score 0-3;\n3. Histologically confirmed diffuse large B-cell lymphoma (DLBCL) \\[diagnostic criteria according to WHO 2008\\];\n4. CD19 positive (immunohistochemistry or flow cytometry).\n5. DLBCL refractory or relapse is defined as: complete remission is not achieved after 2-line treatment; let What disease progress occurs during treatment, or the disease stability time is equal to or less than 6 months; Or autologous hematopoietic stem Disease progression or recurrence within 12 months after cell transplantation;\n6. Previous treatment for patients with diffuse large B cell lymphoma must include rituximab (CD20 monoclonal antibody) and anthracyclines;\n7. At least one measurable lesion is required, and any lymph node lesion with a length greater than 1.5cm or extranodal lesion is required If any length diameter is greater than 1.0 cm, the lesions on PET-CT scan have uptake (SUV is larger than liver blood pool);\n8. Absolute value of peripheral blood neutrophils ≥ 1000\u002F μ l. Platelets ≥ 45000\u002F μ l\n9. Heart, liver and kidney functions: creatinine \\\u003C 1.5mg\u002FdL; ALT\u002FAST Less than 2.5 times of normal upper limit; Total bilirubin \\\u003C 1.5mg\u002FdL; Cardiac ejection fraction (EF) ≥ 50%;\n10. Have sufficient understanding and voluntarily sign the informed consent form;\n11. People with fertility must be willing to use contraceptive methods;\n12. According to the judgment of the researcher, the expected survival period is at least 4 months;\n13. Willing to follow the visit schedule, administration plan, laboratory inspection and other test steps.\n\nExclusion Criteria:\n\n1. Have a history of other tumors;\n2. Autologous hematopoietic stem cell transplantation was performed within 6 weeks;\n3. Any target CAR-T treatment was performed within 3 months before this CAR-T treatment;\n4. Previously used any commercially available PD-1 monoclonal antibody;\n5. Cytotoxic drugs, glucocorticoids and other targeted drugs were received within 2 weeks before cell collection;\n6. Active autoimmune diseases;\n7. Uncontrollable active bacterial and fungal infections;\n8. HIV infection and syphilis infection; Active hepatitis B or hepatitis C: hepatitis B: HBV-DNA ≥ 1000 IU\u002FmL; Hepatitis C: HCV RNA is positive and liver function is abnormal.\n9. Known central nervous system lymphoma.",{"count":204,"type":21},24,[206],"PHASE1","The goal of this clinical trial is to test CD19-7×19 CAR-T cells combined with Tislelizumab in refractory and relapsed diffuse large B lymphoma. The main question\\[s\\] it aims to answer are:\n\nquestion 1：What is the safety of CD19-7×19 CAR-T cells combined with Tislelizumab in the treatment of relapsed or refractory diffuse large B-cell lymphoma.\n\nquestion 2：What is the efficacy of CD19-7×19 CAR-T cells combined with Tislelizumab in the treatment of relapsed or refractory diffuse large B-cell lymphoma.\n\nParticipants will be asked to receive clinical evaluation before CAR-T, including physical examination, blood routine test, biochemical test, imaging test, etc.Peripheral blood lymphocytes will be collected for preparation of CAR-T cells after enrollment. Pretreatment chemotherapy with fludarabine and cyclophosphamide will be used before CAR-T infusion. On the 31st day after CAR-T infusion, Tislelizumab 200mg was given once every 21 days for 6 cycles. Participants will be required to report concomitant medication and adverse events, and their disease was evaluated throughout the study.",[209],"Diffuse Large B-cell Lymphoma","2022-12-12",{"date":212,"type":42},"2022-12-21",{"date":214,"type":21},"2022-12",{"date":216,"type":21},"2026-12",{"name":48,"class":49},2,""]